You are here: Industry Insights > Biocon

News List

Mylan, Biocon Launch Trastuzumab Biosimilar, Ogivri in the U.S. americanpharmaceuticalreview
December 30, 2019
Mylan and Biocon announced the U.S. launch of Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin® (trastuzumab).
Biocon to unlock affordable access to insulins globally biospectrumasia
December 09, 2019
Biocon Biologics, a fully integrated 'pure play' global biosimilars organisation, is taking forward its mission of unlocking affordable access to quality insulins for people with diabetes across the world.
Biocon announces price reduction for insulin biospectrumasia
September 27, 2019
The IoT has opened up a world of possibilities in health: when connected to the Internet, ordinary medical devices can collect invaluable additional data, give extra insight into symptoms and trends, enable remote care and generally give people more contr
Biocon Malaysia unit receives EU GMP certification biospectrumasia
August 25, 2019
Biocon’s Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity
Biocon’s Malaysia Insulin glargine facility receives Certificate of GMP expresspharma
August 23, 2019
The approval expands Biocon’s capacities, with new large scale devices facility coming up to speed to serve growing needs of people with diabetes in EU
Biocon, Mylan launch Ogivri in Australia biospectrumasia
August 04, 2019
Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme (PBS).
Mylan and Biocon launch first Trastuzumab Biosimilar, Ogivri, in Australia expresspharma
August 02, 2019
Biocon and Mylan NV have announced the launch of Ogivri (trastuzumab), a biosimilar to Herceptin (trastuzumab), in Australia for treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcin
Biocon, Mylan launch first Trastuzumab Biosimilar Ogivri in Australia biospectrumasia
August 01, 2019
Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme (PBS).
Biocon Q1FY20 Revenue grows by 25 per cent expresspharma
July 30, 2019
Biocon has announced its consolidated financial results for the fiscal first quarter ended June 30, 2019. Commenting on the highlights, Chairperson and Managing Director, Kiran Mazumdar-Shaw stated ...
USFDA issues 12 observations for three Biocon units in Malaysia expresspharma
July 11, 2019
Biotechnology major Biocon has said US health regulator has issued 12 observations after the inspection of three of its units in Malaysia.

Previous page 1 2 3 4 5 6 Next page